Active Biotech presents data on paquinimod at EULAR 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Active Biotech presents data on paquinimod at EULAR 2014

Lund, Sweden, June 11, 2014, Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data related to the drug candidate paquinimod (57-57) for the treatment of systemic sclerosis, at the scientific conference "EULAR Annual European Congress of Rheumatology" held in Paris on June 11-14, 2014. Active Biotech presentations include: - (FRI0496) An open-label study to evaluate biomarkers and safety in systemic sclerosis (SSc) patients treated with paquinimod (ABR-215757). Hesselstrand R., Distler J.H., Riemekasten G., Törngren M., Nyhlén H. C., Stenström M., Andersson F., Eriksson H., Sparre B., Tuvesson H., Distler O. In this study, nine patients were treated with paquinimod 3 mg/day for eight weeks. The primary endpoint of the study was changes in disease related biomarkers.  Paquinimod was well tolerated and effects on biomarkers relevant for SSc were observed during treatment. - (FRI0516) Paquinimod (ABR-215757), an immunomodulatory compound, reduces fibrosis in the tight-skin 1 (TSK-1) model for systemic sclerosis. Stenström M., Nyhlén H. C., Nilsson M., Eriksson H., Törngren M., Distler J.H., Distler O., Sparre B., Tuvesson H. The purpose of this pre-clinical study was to investigate the effects of paquinimod in an experimental disease model for systemic sclerosis. The results show that paquinimod reduces development of skin fibrosis in this disease model. For more detailed information, please see www.eular.org. About paquinimod Paquinimod is a quinoline compound primarily intended for the treatment of systemic sclerosis. This rare disease is classified as an orphan drug indication. In 2011 and 2014, paquinimod was granted orphan medicinal product status in Europe and US for the indication systemic sclerosis. The Orphan Medicinal Product Designation is implemented to promote the development of drugs that may provide significant benefit to patients suffering from rare diseases identified as life-threatening or chronically debilitating. About Active Biotech Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is laquinimod (NERVENTRA®), an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis. Also tasquinimod for the treatment of prostate cancer, with a unique mode of action, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn's and Lupus. The company has two additional projects in clinical development, ANYARA primarily for the treatment of renal cell cancer and the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information. For further information, please contact: Tomas Leanderson, President & CEO Tel: +46 (0)46 19 20 95 Email: tomas.leanderson@activebiotech.com Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00 Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on June 11, 2014. [HUG#1791728]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MGM China Hits Record Highs Amid Market Challenges

Updated Category News Views 59

Highs Amid Headwinds: MGM China's Standout Quarter Rolling into one's portfolio, MGM China isn't just coasting along—it's smashing some records, despite fierce headwinds. It's not all smooth sailing in Macau's gaming scene, but MGM China has hammered out its third-quarter results with gusto, setting new records for revenue and adjusted EBITDA. These folks aren't just...

Continue Reading
Markel's Reinsurance Shift with $4.8B Deal: Strategic Move?

Updated Category News Views 132

Weaving Through Complex Insurance Terrain When Markel Insurance pulls a move on the chessboard that involves $4.8 billion in subject reserves, we better pay attention. The insurance bigwig has inked a reinsurance deal with Enstar. This plan, they say, will help them focus more on their specialty insurance game while tidying up the loose ends in their global reinsurance...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 125

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Follett's $2.5M Investment Revamps UF Bookstore Experience

Updated Category News Views 44

A New Era for the UF Bookstore If you've ever strolled through a dusty college bookstore and found yourself yearning for a bit of flair, Gainesville has got a surprise for you. The University of Florida, in collaboration with Follett Higher Education, just splashed $2.5 million to turn their bookstore into a dazzling retail wonderland. Not just about flogging textbooks...

Continue Reading
Vicuna Air Unveils Pet-Friendly European Routes

Updated Category News Views 12

Paws in the Sky: Vicuna Air's New Venture Look, when you hear about airlines, you're usually thinking delays, cramped seats, and overpriced peanuts—not four-legged companions jet-setting across the Atlantic. Yet, here comes Vicuna Air, flipping the script with their first continental European flights this October. They've got an ace up their sleeve: Brussels, now a...

Continue Reading
Ryde Group Faces Class Action: Key Investor Takeaways

Updated Category News Views 62

Ryde Group's Tumble: More Than Just Market Volatility When RYDE shares nosedived like a lead balloon, it wasn't due to a market hiccup—it was a darn mess fueled by alleged manipulation. At the heart of this crash are accusations of a blatant pump-and-dump scheme that allegedly swindled investors out of millions. Pump-and-Dump: The Dirty Mechanics This ain't your regular...

Continue Reading
MPLX Adds Industry Veterans to Board Leadership

Updated Category News Views 25

A New Era for MPLX's Board Nothing shakes up the scene like announcing two heavyweights joining the board, and that's exactly what MPLX LP (NYSE: MPLX) just pulled off. Micheal G. Dunn and Bruce L. Niemeyer are coming onboard, effective November 1, 2026. With pedigrees that could make any industry insider nod in approval, these guys bring decades of experience to the...

Continue Reading
Tata's $450M Bet on India's AI Infrastructure

Updated Category News Views 28

The Big Bet on AI Infrastructure Here comes Tata Communications, tossing nearly USD 450 million into the pot, betting on a vision that could change India's digital backbone. This isn't just some drop in the bucket; they're talking about laying down 10,000 kilometers of fiber for India's AI super highway. It's a gutsy move, and frankly, it's about time someone shook things...

Continue Reading
Historic Williamsburg Loft Gets a Modern Makeover

Updated Category News Views 0

Breathing New Life into a Brooklyn Classic Alright, picture this: You're stepping into a century-old Brooklyn loft, expecting dust, aged wood, maybe a ghost or two. What you actually find is art wrapped in brass with a splash of modern flair. This ain't just any loft, folks—it's the latest trophy on the mantle for Gallery KBNY, a design-build firm known for its...

Continue Reading
Personalized Senior Living Guidance Finds Home in South Jersey

Updated Category News Views 66

Shaunique Adams and Her Mission in South Jersey In a world where compassion sometimes feels like it's on short supply, Shaunique Adams is making sure it's at the forefront of her mission. Having experienced the emotional whirlwind of caregiving firsthand, Adams has transformed her personal journey into a mission to serve families navigating similar paths. Through Trua...

Continue Reading

Top 5 Most Recently Viewed Articles

Plaza Retail REIT to Host Conference Call on Financial Results

Updated Category News Views 153

Plaza Retail REIT Announces Financial Results Conference Call Plaza Retail REIT, recognized as a leading retail property owner and developer, is excited to announce a live conference call with its senior management team. This upcoming event will focus on discussing the company's financial results for the third quarter of 2025. The call is set to take place on Thursday,...

Continue Reading
Shimmick Corporation Second Quarter Update: Growth and Strategy

Updated Category News Views 114

Shimmick Corporation Reports Strong Financial Performance In a recent announcement, Shimmick Corporation (NASDAQ: SHIM), a prominent infrastructure solutions provider, revealed its financial results for the second quarter. The company has shown remarkable growth in various projects aimed at enhancing water, climate resilience, energy transition, and sustainable...

Continue Reading
Canadian Cannabis Exports Expand Globally with PR Expertise

Updated Category News Views 158

The Global Expansion of Canadian Cannabis Companies Canada is establishing itself as a frontrunner in the international medical cannabis market. As producers look to broaden their horizons, the need for strategic communication becomes essential. With the legalization of cannabis on a federal level, Canadian companies are well-positioned to meet the growing global demand...

Continue Reading
Autolus Therapeutics: Key Developments Boosting Stock Value

Updated Category News Views 143

Positive Developments for Autolus Therapeutics' Stock The recent news from the U.K.'s National Institute for Health and Care Excellence has ignited interest in Autolus Therapeutics plc (NASDAQ: AUTL). The organization has released draft guidance that endorses the use of Aucatzyl (obecabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor...

Continue Reading
Revolutionizing Digital Security in Australia and New Zealand

Updated Category News Views 205

Cyabra Partners with Aquion for Enhanced Digital Security New York, NY, April 09, 2025 -- Cyabra Strategy Ltd. (“Cyabra”), a renowned platform specializing in real-time disinformation detection, has forged a significant partnership with Aquion Pty Ltd, a reliable distributor of cybersecurity solutions. This collaboration aims to deploy Cyabra’s cutting-edge AI...

Continue Reading